Inovio reported a first-quarter loss of $10 million, or 5 cents a share, compared to a loss of $6.6 million, or 4 cents a share, in the same period one year earlier. This was slightly wider than the consensus estimate of a loss of 4 cents a share.
Revenue totaled $2.4 million, up year over year from $1.5 million. This surpassed analysts' estimates of $1.41 million; however, this increase was due primarily to $1.4 million attributable to the company's agreement with Roche. This portion of revenue mostly consisted of development fees paid for work Inovio performed in the first quarter.
Must Read: Warren Buffett's 10 Favorite Growth StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock was down 6.3% to $2.02 at 10:50 a.m. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts